Magnetic nanoparticles in the imaging of tumor angiogenesis

Applied Sciences (Switzerland)

Volumn 2, Issue 2, 2012, Pages 525-534

  McDermott, Shaunagh ^a   Guimaraes, Alexander R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Angiogenesis; Magnetic resonance imaging; Ultrasmall superparamagnetic iron oxide

Indexed keywords

EID: 84871836303     PISSN: None     EISSN: 20763417     Source Type: Journal    
DOI: 10.3390/app2020525     Document Type: Review

References (42)

1. Folkman, J. Angiogenesis research: From laboratory to clinic. Forum (Genova) 1999, 9, 59-62
2. Bergers, G.; Benjamin, L.E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer. 2003, 3, 401-410
3. Hanahan, D.; Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86, 353-364
4. Folkman, J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 2002, 29, 15-18
5. Jain, R.K. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005, 307, 58-62
6. Tong, R.T.; Boucher, Y.; Kozin, S.V.; Winkler, F.; Hicklin, D.J.; Jain, R.K. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 2004, 64, 3731-3736
7. Stohrer, M.; Boucher, Y.; Stangassinger, M.; Jain, R.K. Oncotic pressure in solid tumors is elevated. Cancer Res. 2000, 60, 4251-4255
8. Padera, T.P.; Stoll, B.R.; Tooredman, J.B.; Capen, D.; di Tomaso, E.; Jain, R.K. Pathology: Cancer cells compress intratumour vessels. Nature 2004, 427, 695
9. Helmlinger, G.; Yuan, F.; Dellian, M.; Jain, R.K. Interstitial pH and pO2 gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation. Nat. Med. 1997, 3, 177-182
10. Teicher, B.A. A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics ? mechanism(s) of interaction). Cancer Metastasis Rev. 1996, 15, 247-272
11. Wouters, B.G.; Brown, J.M. Cells at intermediate oxygen levels can be more important than the "hypoxic fraction" in determining tumor response to fractionated radiotherapy. Radiat Res. 1997, 147, 541-550
12. Jain, R.K. Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J Natl. Cancer Inst. 1989, 81, 570-576
13. Jain, R.K.; Duda, D.G.; Clark, J.W.; Loeffler, J.S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol. 2006, 3, 24-40
14. Sandler, A.; Gray, R.; Perry, M.C.; Brahmer, J.; Schiller, J.H.; Dowlati, A.; Lilenbaum, R.; Johnson, D.H. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 2006, 355, 2542-2550
15. Saltz, L.B.; Clarke, S.; Diaz-Rubio, E.; Scheithauer, W.; Figer, A.; Wong, R.; Koski, S.; Lichinitser, M.; Yang, T.S.; Rivera, F.; et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J. Clin. Oncol. 2008, 26, 2013-2019
16. Jain, R.K. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat. Med. 2001, 7, 987-989
17. Takei, H.; Bhattacharjee, M.B.; Rivera, A.; Dancer, Y.; Powell, S.Z. New immunohistochemical markers in the evaluation of central nervous system tumors: A review of 7 selected adult and pediatric brain tumors. Arch. Pathol. Lab. Med. 2007, 131, 234-241
18. Carmeliet, P.; Jain, R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407, 249-257
19. Brown, E.B.; Campbell, R.B.; Tsuzuki, Y.; Xu, L.; Carmeliet, P.; Fukumura, D.; Jain, R.K. In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy. Nat. Med. 2001, 7, 864-868
20. Corot, C.; Robert, P.; Idee, J.M.; Port, M. Recent advances in iron oxide nanocrystal technology for medical imaging. Adv. Drug Deliv. Rev. 2006, 58, 1471-1504
21. Enochs, W.S.; Harsh, G.; Hochberg, F.; Weissleder, R. Improved delineation of human brain tumors on MR images using a long-circulating, superparamagnetic iron oxide agent. J. Magn. Reson. Imaging. 1999, 9, 228-232
22. Persigehl, T.; Bieker, R.; Matuszewski, L.; Wall, A.; Kessler, T.; Kooijman, H.; Meier, N.; Ebert, W.; Berdel, W.E.; Heindel, W.; et al. Antiangiogenic tumor treatment: early noninvasive monitoring with USPIO-enhanced MR imaging in mice. Radiology 2007, 244, 449-456
23. Tropres, I.; Grimault, S.; Vaeth, A.; Grillon, E.; Julien, C.; Payen, J.F.; Lamalle, L.; Decorps, M. Vessel size imaging. Magn. Reson. Med. 2001, 45, 397-408
24. Brown, J.M.; Giaccia, A.J. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 1998, 58, 1408-1416
25. Bremer, C.; Mustafa, M.; Bogdanov, A., Jr., Ntziachristos, V.; Petrovsky, A.; Weissleder, R. Steady-state blood volume measurements in experimental tumors with different angiogenic burdens a study in mice. Radiology 2003, 226, 214-220
26. Boxerman, J.L.; Hamberg, L.M.; Rosen, B.R.; Weisskoff, R.M. MR contrast due to intravascular magnetic susceptibility perturbations. Magn. Reson. Med. 1995, 34, 555-566
27. Dennie, J.; Mandeville, J.B.; Boxerman, J.L.; Packard, S.D.; Rosen, B.R.; Weisskoff, R.M. NMR imaging of changes in vascular morphology due to tumor angiogenesis. Magn. Reson. Med. 1998, 40, 793-799
28. Hyodo, F.; Chandramouli, G.V.; Matsumoto, S.; Matsumoto, K.; Mitchell, J.B.; Krishna, M.C.; Munasinghe, J.P. Estimation of tumor microvessel density by MRI using a blood pool contrast agent. Int. J. Oncol. 2009, 35, 797-804
29. Gambarota, G.; Leenders, W.; Maass, C.; Wesseling, P.; van der Kogel, B.; van Tellingen, O.; Heerschap, A. Characterisation of tumour vasculature in mouse brain by USPIO contrastenhanced MRI. Br. J. Cancer. 2008, 98, 1784-1789
30. Pathak, A.P.; Rand, S.D.; Schmainda, K.M. The effect of brain tumor angiogenesis on the in vivo relationship between the gradient-echo relaxation rate change (DeltaR2*) and contrast agent (MION) dose. J. Magn. Reson. Imaging. 2003, 18, 397-403
31. Kiselev, V.G.; Strecker, R.; Ziyeh, S.; Speck, O.; Hennig, J. Vessel size imaging in humans. Magn. Reson. Med. 2005, 53, 553-563
32. Lemasson, B.; Christen, T.; Tizon, X.; Farion, R.; Fondraz, N.; Provent, P.; Segebarth, C.; Barbier, E.L.; Genne, P.; Duchamp, O.; et al. Assessment of multiparametric MRI in a human glioma model to monitor cytotoxic and anti-angiogenic drug effects. NMR Biomed. 2011, 24, 473-482
33. Valable, S.; Lemasson, B.; Farion, R.; Beaumont, M.; Segebarth, C.; Remy, C.; Barbier, E.L. Assessment of blood volume, vessel size, and the expression of angiogenic factors in two rat glioma models: A longitudinal in vivo and ex vivo study. NMR Biomed. 2008, 21, 1043-1056
34. Beaumont, M.; Lemasson, B.; Farion, R.; Segebarth, C.; Remy, C.; Barbier, E.L. Characterization of tumor angiogenesis in rat brain using iron-based vessel size index MRI in combination with gadolinium-based dynamic contrast-enhanced MRI. J. Cereb. Blood Flow Metab. 2009, 29, 1714-1726
35. Guimaraes, A.R.; Ross, R.; Figuereido, J.L.; Waterman, P.; Weissleder, R. MRI with magnetic nanoparticles monitors downstream anti-angiogenic effects of mTOR inhibition. Mol. Imaging Biol. 2011, 13, 314-320
36. Guimaraes, A.R.; Rakhlin, E.; Weissleder, R.; Thayer, S.P. Magnetic resonance imaging monitors physiological changes with antihedgehog therapy in pancreatic adenocarcinoma xenograft model. Pancreas 2008, 37, 440-444
37. Persigehl, T.; Matuszewski, L.; Kessler, T.; Wall, A.; Meier, N.; Ebert, W.; Berdel, W.E.; Heindel, W.; Mesters, R.; Bremer, C. Prediction of antiangiogenic treatment efficacy by iron oxide enhanced parametric magnetic resonance imaging. Invest. Radiol. 2007, 42, 791-796
38. Ring, J.; Persigehl, T.; Remmele, S.; Heindel, W.; Dahnke, H.; Bremer, C. Monitoring of bevacizumab-induced antiangiogenic treatment effects by "steady state" ultrasmall superparamagnetic iron oxide particles magnetic resonance imaging using robust multiecho DeltaR2* relaxometry. Invest Radiol. 2011, 46, 326-330
39. Montet, X.; Montet-Abou, K.; Reynolds, F.; Weissleder, R.; Josephson, L. Nanoparticle imaging of integrins on tumor cells. Neoplasia 2006, 8, 214-222
40. Zhang, C.; Jugold, M.; Woenne, E.C.; Lammers, T.; Morgenstern, B.; Mueller, M.M.; Zentgraf, H.; Bock, M.; Eisenhut, M.; Semmler, W.; et al. Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Cancer Res. 2007, 67, 1555-1562
41. Boles, K.S.; Schmieder, A.H.; Koch, A.W.; Carano, R.A.; Wu, Y.; Caruthers, S.D.; Tong, R.K.; Stawicki, S.; Hu, G.; Scott, M.J.; et al. MR angiogenesis imaging with Robo4-vs. alphaVbeta3-targeted nanoparticles in a B16/F10 mouse melanoma model. Faseb J. 2010, 24, 4262-4270
42. Schmieder, A.H.; Caruthers, S.D.; Zhang, H.; Williams, T.A.; Robertson, J.D.; Wickline, S.A.; Lanza, G.M. Three-dimensional MR mapping of angiogenesis with a5β1(a-β3)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model. Faseb J. 2008, 22, 4179-4189